Clinical validity and clinical utility of Ki67 in early breast cancer

Kreipe, Hans; Harbeck, Nadia; Christgen, Matthias

doi:10.1177/17588359221122725

Cited by 18 publications

(13 citation statements)

References 51 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results suggested that the GP‐20@Gla group grew fastest because Ki67 is the most crucial protein marker of cell proliferation. [ 30 ] This study's results of CD31 and Ki67 IF staining assay were interactive. A higher degree of vascularization is conducive to transporting oxygen and nutrients, which improves the speed and quality of tissue regeneration.…”

Section: Resultsmentioning

confidence: 99%

Local Delivery of Glabridin by Biomolecular Microneedle to Accelerate Infected Wound Healing

Chen,

Hu,

Wang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Applying antibacterial polymers and pro‐regenerative small molecules are two individual strategies for accelerating wound healing. However, integrating those two unique approaches into one therapeutic platform that meets clinical requirements is still a challenge. Herein, a series of antibacterial gelatin methacrylate (GelMA)/ε‐polylysine (ε‐PL) composite hydrogels (termed as GP‐n HGs, n = 0, 10, 20 and 30, respectively) were innovatively fabricated by ultraviolet light (UV) crosslinking. The GP‐n HGs were proved to be broad‐spectrum antibacterial and biocompatible. Among those GP‐n HGs, the GP‐20 HG was selectively processed into microneedle following a mold‐casting method. Then, the glabridin was loaded into those needles to produce composite microneedle termed GP‐20@Gla MN. An S. aureus‐infected full‐thickness defect model in rats was created to evaluate the wound‐healing effect of GP‐20@Gla MN. Furthermore, an RNA sequencing assay was performed to explore the possible molecular mechanisms of glabridin in promoting tissue regeneration, and many positive routes have been summarized. This work is of significant novelty in fulfilling complex clinical needs by simultaneously optimizing the advanced microneedles' chemical compositions and physical structures. This work will provide a promising therapeutic platform for treating infected and chronic wounds.This article is protected by copyright. All rights reserved

show abstract

Section: Resultsmentioning

confidence: 99%

Local Delivery of Glabridin by Biomolecular Microneedle to Accelerate Infected Wound Healing

Chen,

Hu,

Wang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Recent studies have discovered that Ki67 can be used as a diagnostic and prognostic biomarker in renal cancer ( 6 ), breast cancer ( 20 , 22 ), ovarian cancer ( 23 ), craniopharyngioma ( 24 ) and neuroendocrine neoplasms ( 25 ). However, the prognostic role of Ki67 in prostate cancer remains ambiguous and has not been thoroughly explored.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, most studies have been conducted on the predictive and clinical effectiveness of Ki67, but few studies have utilized the characteristics of Ki67 and the ADC in combination. We strongly believe in the importance of ADCs in PCa and hold the opinion that Ki67 can be applied in combination with postoperative PSA testing and imaging parameters (i.e., the ADC) to improve specificity and sensitivity ( 9 , 20 , 21 ). The aim of this study was to determine whether Ki67 had any predictive value for prostate cancer patients who received surgery and endocrine therapy.…”

Section: Introductionmentioning

confidence: 99%

Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy

Che

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundProstate-specific antigen (PSA) is a critical part of prostate cancer (PCa) screening, diagnosis, staging, and prognosis. However, elevated PSA levels can also be caused by several external factors. To improve the specificity and sensitivity of PSA in clinical practice, we explored whether markers or parameters may be used as prognostic targets for PCa by long-term follow-up.MethodsA total of 121 PCa patients who underwent laparoscopic radical prostatectomy (LRP) were included in our study, all of whom underwent imaging and preoperative pathological diagnosis. Endocrine therapy has long been applied to treat postoperative patients. The prognosis of enrolled patients was followed, and statistics were collected. Spearman's correlation analysis was applied to examine the relationship and clinical parameters. Kaplan–Meier analysis was used to process the clinical variables of PCa patients. Cox proportional hazards regression analysis was applied to examine univariate and multivariate variables.ResultsThe Gleason score (GS), PSA, clinical stage, nerve infiltration, organ confinement, Ki67 and apparent diffusion coefficient (ADC) were significantly associated with prognosis (all P < 0.05). The GS, PSA, clinical stage, organ confined, Ki67, nerve infiltration and ADC were included in the multivariate analysis (all P < 0.05). Ultimately, Ki67 and the ADC were found to provide meaningful predictive information (both P < 0.05).ConclusionsKi67 and the ADC may be clinically and analytically valid prognostic biomarkers and imaging parameters in PCa. They may be useful for predicting the prognosis and risk of PCa patients undergoing postoperative routine endocrine therapy.

show abstract

“…Given that the manual quantification of Ki-67 + tumor cells is time consuming and cumbersome, the computerized quantification of Ki-67 + cancer cells has been extensively studied [9,15,16]. Despite such efforts, automated differentiation between normal healthy prostate tissue and prostate cancer still represents the most significant hurdle in its routine use, which is why the cumbersome assessment of Ki-67 LI, also known from breast cancer, in at least 200-500 tumor cells is currently not done in routine clinical practice [17,18].…”

Section: Introductionmentioning

confidence: 99%

Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry

Blessin

Cheng

Mandelkow

et al. 2023

The Journal of Pathology

View full text Add to dashboard Cite

The Ki-67 labeling index (Ki-67 LI) is a strong prognostic marker in prostate cancer, although its analysis requires cumbersome manual quantification of Ki-67 immunostaining in 200-500 tumor cells. To enable automated Ki-67 LI assessment in routine clinical practice, a framework for automated Ki-67 LI quantification, which comprises three different artificial intelligence analysis steps and an algorithm for cell-distance analysis of multiplex fluorescence immunohistochemistry (mfIHC) staining, was developed and validated in a cohort of 12,475 prostate cancers. The prognostic impact of the Ki-67 LI was tested on a tissue microarray (TMA) containing one 0.6 mm sample per patient. A 'heterogeneity TMA' containing three to six samples from different tumor areas in each patient was used to model Ki-67 analysis of multiple different biopsies, and 30 prostate biopsies were analyzed to compare a 'classical' bright field-based Ki-67 analysis with the mfIHC-based framework. The Ki-67 LI provided strong and independent prognostic information in 11,845 analyzed prostate cancers (p < 0.001 each), and excellent agreement was found between the framework for automated Ki-67 LI assessment and the manual quantification in prostate biopsies from routine clinical practice (intraclass correlation coefficient: 0.94 [95% confidence interval: 0.87-0.97]). The analysis of the heterogeneity TMA revealed that the Ki-67 LI of the sample with the highest Gleason score (area under the curve [AUC]: 0.68) was as prognostic as the mean Ki-67 LI of all six foci (AUC: 0.71 [p = 0.24]). The combined analysis of the Ki-67 LI and Gleason score obtained on identical tissue spots showed that the Ki-67 LI added significant additional prognostic information in case of classical International Society of Urological Pathology grades (AUC: 0.82 [p = 0.002]) and quantitative Gleason score (AUC: 0.83 [p = 0.018]). The Ki-67 LI is a powerful prognostic parameter in prostate cancer that is now applicable in routine clinical practice. In the case of multiple cancer-positive biopsies, the sole automated analysis of the worst biopsy was sufficient.

show abstract

Clinical validity and clinical utility of Ki67 in early breast cancer

Cited by 18 publications

References 51 publications

Local Delivery of Glabridin by Biomolecular Microneedle to Accelerate Infected Wound Healing

Local Delivery of Glabridin by Biomolecular Microneedle to Accelerate Infected Wound Healing

Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy

Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry

Contact Info

Product

Resources

About